Structure−Activity Relationships for a Novel Series of Dopamine D2-like Receptor Ligands Based on N-Substituted 3-Aryl-8-azabicyclo[3.2.1]octan-3-ol
- 6 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (19) , 6095-6109
- https://doi.org/10.1021/jm800532x
Abstract
Discovering dopamine D2-like receptor subtype-selective ligands has been a focus of significant investigation. The D2R-selective antagonist 3-[4-(4-chlorophenyl)-4-hydroxypiperidinyl]methylindole (1, L741,626; Ki(D2R/D3R) = 11.2:163 nM) has previously provided a lead template for chemical modification. Herein, analogues have been synthesized where the piperidine was replaced by a tropane ring that reversed the selectivity seen in the parent compound, in human hD2LR- or hD3R-transfected HEK 293 cells (31, Ki(D2R/D3R) = 33.4:15.5 nM). Further exploration of both N-substituted and aryl ring-substituted analogues resulted in the discovery of several high affinity D2R/D3R ligands with 3-benzofurylmethyl-substituents (e.g., 45, Ki(D2R/D3R) = 1.7:0.34 nM) that induced high affinity not achieved in similarly N-substituted piperidine analogues and significantly (470-fold) improved D3R binding affinity compared to the parent ligand 1. X-ray crystallographic data revealed a distinctive spatial arrangement of pharmacophoric elements in the piperidinol vs tropine analogues, providing clues for the diversity in SAR at the D2 and D3 receptor subtypes.Keywords
This publication has 55 references indexed in Scilit:
- S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side EffectsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- S33138 [N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- S33138 [N-[4-[2-[(3 aS,9 bR)-8-Cyano-1,3 a,4,9 b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Pharmacological Actions of NGB 2904, a Selective Dopamine D3Receptor Antagonist, in Animal Models of Drug AddictionCNS Drug Reviews, 2007
- REVIEW: New developments in the pharmacotherapy of cocaine abuseAddiction Biology, 2007
- Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SARBioorganic & Medicinal Chemistry Letters, 2007
- Cocaine Dependence and D2 Receptor Availability in the Functional Subdivisions of the Striatum: Relationship with Cocaine-Seeking BehaviorNeuropsychopharmacology, 2004
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- The Synthesis of an Indazole Analog of DL-TryptophanJournal of the American Chemical Society, 1952
- Cyclic Polyolefins. XVI. Phenylcycloheptatriene and Phenylcycloöctatriene1Journal of the American Chemical Society, 1951